A potential diagnostic marker for patients with polycystic ovary syndrome-anti-Müllerian hormone: a Meta analysis

Abstract

Objective To evaluate the diagnostic value of serum anti-Mullerian hormone (AMH) in patients with polycystic ovary syndrome (PCOS). Methods All literatures in English and Chinese for differential diagnosis of PCOS by serum AMH were collected from January 1950 to May 2017. Data were extracted and assessed according to established criteria and QUADAS standard. Sensitivity, specificity and diagnostic odds ratio were pooled with Meta-Disc1.4 software. Summary receiver operating characteristics (SROC) curve analysis was used to evaluate the diagnostic value of serum AMH. Results Twenty-eight studies were included in the Meta-analysis. The sensitivity, specificity and diagnostic odds ratio of serum AMH alone in the diagnosis of PCOS were 0.77, 0.84 and 14.97. As the AMH was substitution of polycystic ovary morphology (PCOM) and combined with either oligo/amenorrhea or hyperandrogenism data, the sensitivity, specificity and diagnostic odds ratio of serum AMH were 0.85, 0.98 and 343.18, respectively. Moreover, concerning the area under curve (AUC) of AMH level by SROC, the AUC was 0.864 0 in single serum AMH and 0.985 8 in AMH combined with aforementioned clinical features, which was significantly different (Z=4.21, P<0.01). Conclusion AMH might be a potential diagnostic value for PCOS patients. Moreover, AMH replaced PCOM and combined with aforementioned clinical features was a more accurate diagnostic marker. Key words: Polycystic ovary syndrome (PCOS); Anti-Mullerian hormone (AMH); Meta-analysis; Diagnostic test